Champions Oncology, Inc. (CSBR) is a US-based leading technology-enabled company dedicated to personalizing the development and use of therapeutics for oncology. The firm started as Champions Biotechnology in 2007 and changed its name to Champions Oncology in 2011, reflecting its evolution as a leader in the burgeoning field of oncology personalized medicine. The company is publicly traded and listed on NASDAQ as CSBR.
Champions Oncoogy has revolutionized the way oncology is practiced by providing an end-to-end range of research and development solutions, thereby transforming the hope of patients battling cancer into success stories. With their head operations at Hackensack, NJ, they have satellite locations around the globe, including in the United Kingdom and Singapore.
The company’s key product, TumorGraft, is recognized due to its exceptional predictability. This technology involves the implantation of human tumor samples into immune-deficient mice, allowing personalized animal models that mirror the patient's unique cancer biology. This technique has proved transformative and innovative in efforts to enhance cancer therapy effectiveness, directing the development of personalized treatment plans and providing the tools to develop and trial novel cancer agents.
In addition to TumorGraft, Champions Oncology is also recognized for its mastery in pharmacology, therapeutic expertise, and bioinformatics, giving the company a competitive edge in the industry. Champions Oncology’s technologies in oncology research has been utilized by numerous pharmaceutical and biotech companies across the globe, including academic centers, and government research organizations.
Champions Oncology, Inc's primary revenue comes from research products and services offered to bio-pharma companies, academic institutions, and individual patients. Their unique approach and proven technology platforms have resulted in substantial contributions to the pharmaceutical space, streamlining the road to developing new treatments and personalizing medicine.
Overall, Champions Oncology, Inc. (CSBR) embodies a paradigm change in translational oncology research. Their pioneering approach and technology solutions have not just fast-tracked the development of new cancer therapies but have also facilitated a more effective way to manage and treat cancer. Their relentless work, combined with advanced science, makes them a true champion in oncological research and service provision.